CJC-1295 (No-DAC) + Ipamorelin

CJC-1295 + Ipamorelin Research Peptide Blend

Dual-pathway GH signalling research for scientific and laboratory investigation.

CJC-1295 and Ipamorelin are two synthetic research compounds studied for their effects on the GH axis through distinct but complementary signalling pathways. CJC-1295 is a modified analogue of GHRH, while Ipamorelin is a synthetic pentapeptide that acts as an agonist at the GH secretagogue receptor, also known as the ghrelin receptor or GHSR-1a.

Because the two compounds act through different receptor systems, their combination has become a subject of laboratory interest in research examining GH secretion, pituitary signalling, hypothalamic regulation, receptor pharmacology and the relationship between GH and IGF-1.

The combination should not be described as a single peptide. It is a blend of two separate research compounds with different structures, receptor targets and pharmacological characteristics. CJC-1295 primarily investigates the GHRH receptor pathway, while Ipamorelin is studied through the GH secretagogue receptor pathway.

Understanding CJC-1295

CJC-1295 was developed as a long-acting analogue of a human GH-releasing factor. Native GHRH has a short biological duration because it is rapidly degraded. CJC-1295 with drug affinity complex (DAC) was engineered to resist enzymatic breakdown and to bind covalently to circulating albumin through a maleimide-containing moiety, substantially prolonging exposure compared with native GHRH.

Early human studies evaluated CJC-1295 in healthy adults through randomised, placebo-controlled, double-blind, ascending-dose trials. These investigations reported sustained, dose-dependent increases in circulating GH and IGF-1. Multiple doses produced evidence of a cumulative pharmacodynamic effect, while IGF-1 remained elevated during the study period. These findings established CJC-1295 as a useful investigational compound for studying prolonged activation of the GHRH receptor pathway.

Research also showed that CJC-1295 increased trough and mean GH secretion while preserving pulsatile release. This distinction is scientifically important because endogenous GH is normally secreted in pulses rather than at a constant rate.

Understanding Ipamorelin

Ipamorelin is structurally and mechanistically different. It is a synthetic pentapeptide and ghrelin mimetic that binds to the GH secretagogue receptor. The National Cancer Institute describes Ipamorelin as a pentapeptide ghrelin mimetic with GH-releasing activity that binds to the ghrelin receptor and stimulates pituitary GH release. It should not be described as binding directly to the IGF-1 receptor.

Ipamorelin was initially characterised as a comparatively selective GH secretagogue. In early preclinical research, it stimulated GH release with less activation of ACTH and cortisol pathways than several earlier GH-releasing peptides under the conditions tested. This does not establish that Ipamorelin is free from off-target effects or that it behaves comparably in other settings.

Why the combination is a focus of research

The scientific rationale for combining CJC-1295 and Ipamorelin arises from their activation of separate components of the GH regulatory system. GHRH receptor agonism and GH secretagogue receptor agonism can produce additive responses in experimental models because the receptors initiate distinct intracellular signalling processes within pituitary somatotroph cells.

GHRH receptor activation is primarily associated with G-protein-mediated increases in cyclic adenosine monophosphate and protein kinase A signalling. The ghrelin receptor primarily couples to Gq/11-related pathways involving phospholipase C, inositol trisphosphate and intracellular calcium mobilisation. Studying the two pathways together can provide insight into how pituitary GH secretion is regulated through overlapping but distinct intracellular pathways.

There is an important evidence limitation. Although CJC-1295 and Ipamorelin have each been investigated independently, high-quality peer-reviewed human research evaluating the specific combined CJC-1295 and Ipamorelin formulation sold by research suppliers is limited. Statements about the blend must therefore be based on the individual pharmacology of each compound rather than presented as established outcomes of the exact combination.

CJC-1295 with and without DAC

The designation CJC-1295 requires careful clarification. In research and commercial markets, the name is sometimes used inconsistently for compounds with and without the drug affinity complex. Authentic CJC-1295 with DAC contains a maleimide-containing extension designed to bind albumin and extend circulation time. Products marketed as “CJC-1295 without DAC” are generally shorter-acting modified GRF analogues and are not pharmacologically identical to CJC-1295 with DAC.

The livvmore product page states whether its CJC-1295 component contains DAC. This distinction affects molecular identity, expected duration of exposure, laboratory design and interpretation of experimental results. The product name, specifications, Certificate of Analysis and product description use consistent terminology.

What the human and preclinical evidence shows

CJC-1295 has human pharmacokinetic and pharmacodynamic data from early controlled studies. Single doses produced dose-dependent increases in GH and IGF-1, with effects persisting for several days. Repeated exposure maintained elevated IGF-1 concentrations during the study period. These studies provide evidence of target-pathway activation but do not establish outcomes for body composition or other commonly promoted uses.

A Phase 2 study was registered to investigate CJC-1295 in people with HIV-associated visceral obesity. The study record is listed as terminated and no results are posted in the registry. A trial registration does not establish activity, safety or regulatory approval.

Ipamorelin has a different research history. It was evaluated in a randomised Phase 2 proof-of-concept study for postoperative ileus following bowel resection. The study investigated gastrointestinal motility through ghrelin-receptor signalling rather than body composition or other promoted uses. Published findings did not establish a statistically significant effect for the primary endpoint.

Preclinical studies have also examined Ipamorelin in rodent models of delayed gastric emptying and postoperative ileus. These studies reported effects on gastrointestinal transit under specific experimental conditions. Findings from animal models should not be generalised beyond the study design or interpreted as proof of effect in humans.

Interpreting GH and IGF-1 research

Research into the GH and IGF-1 axis is complex because these signalling systems influence many tissues and biological processes. GH acts directly through the GH receptor and indirectly through regulation of IGF-1 production. Changes in circulating GH concentrations do not automatically establish a beneficial physiological or applied outcome.

Excessive or prolonged stimulation of GH and IGF-1 pathways may influence energy metabolism pathways, fluid balance, tissue growth and other endocrine processes. The page therefore avoids presenting increased GH or IGF-1 as inherently beneficial.

Anti-doping status

CJC-1295 and Ipamorelin are relevant to anti-doping regulation. The 2026 World Anti-Doping Agency Prohibited List includes CJC-1295 among GHRH analogues and Ipamorelin among GH secretagogues. Athletes should not interpret a research-use-only label as meaning that these compounds are permitted in sport.

How livvmore supplies CJC-1295 + Ipamorelin

At livvmore, CJC-1295 + Ipamorelin is supplied exclusively for laboratory research and analytical investigation. Every batch is supported by product-specific documentation confirming the identity and quantity of both components. Because this is a blended product, the Certificate of Analysis distinguishes total content from the amount of each individual peptide.

Analytical documentation may include high-performance liquid chromatography for purity assessment and mass spectrometry for molecular identity. A single combined purity percentage does not necessarily confirm the correct ratio of two compounds, so blend-ratio verification is particularly important.

Researchers should confirm whether the product contains CJC-1295 with DAC or a shorter-acting modified GRF analogue before designing experiments. They should also account for the compounds’ different receptor targets, pharmacokinetic properties and analytical characteristics.

For laboratory research use only. Not for human or veterinary use.